FNY Investment Advisers’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

FNY Investment Advisers’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,575	Closed	-$514K	–	864
2024 Q2	$514K	Buy	+12,575	New	+$524K	0.35%	55
2024 Q1	–	Sell	-8,000	Closed	-$336K	–	884
2023 Q4	$339K	Buy	+8,000	New	+$230K	0.38%	53
2022 Q1	–	Sell	-15	Closed	–	–	964
2021 Q4	$0	Buy	+15	New	+$529	﹤0.01%	860
2020 Q4	–	Sell	-5,166	Closed	-$53K	–	941
2020 Q3	$53K	Buy	+5,166	New	+$54.5K	0.02%	246

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

FNY Investment Advisers's CERE Position: Q3 2024 in Review

FNY Investment Advisers sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 12,575 shares — an estimated $514K sold.

FNY Investment Advisers first reported a position in CERE in Q3 2020 and held it in 4 quarters. The position peaked at $514K in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

FNY Investment Advisers reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
FNY Investment Advisers sold 12,575 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $514K.
FNY Investment Advisers first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
FNY Investment Advisers's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $514K in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on FNY Investment Advisers's 13F filing for Q3 2024, filed 18 Oct 2024.